Biosimilars: Celltrion paves way for Herceptin copycats in 2018 - Pharmaceutical Technology
US FDA Approves Celltrion's Biosimilar to AG's Breast Cancer Subset Herceptin - Businesskorea
HER2-positive BC Drug Herzuma, Herceptin Biosimilar, Available in US
Teva, Celltrion launch Herceptin biosimilar in US - Globes
Herzuma - FDA prescribing information, side effects and uses
Teva and Celltrion Launch Trastuzumab Biosimilar in U.S. - Big Molecule Watch
Herzuma - FDA prescribing information, side effects and uses
About HERZUMA® (trastuzumab-pkrb) for injection
Celltrion's Herzuma (trastuzumab-pkrb) Biosimilar Product Profile
Supply & Dosage - HERZUMA® (trastuzumab-pkrb) for injection
Herzuma 150 MG Injection By TEVA PHARMACEUTICALS
Teva and Celltrion Healthcare Announce U.S. Availability of HERZUMA® (trastuzumab-pkrb) for Injection | Business Wire
Celltrion and Teva Announce FDA Approval of Herzuma, a Biosimilar to Herceptin, for Treatment of HER2-Overexpressing Breast Cancer | Specialty Pharma Journal
Resources and Support - HERZUMA® (trastuzumab-pkrb) for injection
Are biosimilars the next frontier in drug development? - STAT
Herceptin biosimilar Herzuma now available in the USA
Biosimilar Herzuma Now Available for Breast, Gastric Cancer Treatment - MPR
Celltrion And Teva Catch Up On Canadian Trastuzumab :: Generics Bulletin
Celltrion and Teva Snag Second Biosimilar Approval of a Genentech Drug | BioSpace
Herzuma (trastuzumab biosimilar) for the Treatment of Breast and Gastric Cancers - Clinical Trials Arena
